quinazolines has been researched along with Colorectal Neoplasms in 397 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 50 (12.59) | 18.2507 |
| 2000's | 187 (47.10) | 29.6817 |
| 2010's | 133 (33.50) | 24.3611 |
| 2020's | 27 (6.80) | 2.80 |
| Authors | Studies |
|---|---|
| Artru, P; Auclin, E; Basile, D; Coutzac, C; Dior, M; Dubreuil, O; Faroux, R; Gallois, C; Hafliger, E; Hautefeuille, V; Locher, C; Palmieri, LJ; Pellat, A; Pernot, S; Perret, A; Randrian, V; Taieb, J; Turpin, A | 1 |
| Han, Y; Hua, Z; Jiang, Y; Liu, S; Nie, S; Shu, X; Wang, X; Xu, G; Xu, S; Yang, H; Zhou, C | 1 |
| Liang, J; Liu, J; Liu, S; Lu, L; Pan, F; Shen, R; Wang, J; Xin, FZ; Yang, C; Zhang, N | 1 |
| Cao, Y; Chen, M; Li, J; Lu, M; Peng, Z; Qi, C; Shen, L; Wang, X; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Ahn, D; Bekaii-Saab, T; Walden, D | 1 |
| Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L | 1 |
| Auth, D; Bi, Y; Casak, SJ; Cheng, J; Fashoyin-Aje, LA; Fesenko, N; Fu, W; Horiba, MN; Kluetz, PG; Lemery, SJ; Li, Y; Moore, JN; Pazdur, R; Shen, YL; Yuan, M | 1 |
| Deng, Y; Li, X | 1 |
| Aul, R; Hill, M; Howlett, S; Pinato, DJ | 1 |
| Chen, J; Lin, H; Peng, Y; Wang, J | 1 |
| Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q | 1 |
| Cai, G; Gong, Q; Liang, X; Liu, J; Song, C; Wang, R; Wang, X | 1 |
| Guan, X; Vong, CT; Wang, Y; Xiao, J; Zhao, J; Zheng, X; Zhong, Z | 1 |
| Li, Q; Xie, D; Zhang, PF | 1 |
| Cheng, Y; Du, FC; Duan, ZJ; Fang, FQ; Lei, W; Shi, KG | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, Z; Cheng, Y; Deng, Y; Fan, S; Guo, W; Guo, X; Han, R; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shen, L; Shu, Y; Sun, S; Wang, H; Wang, N; Wang, S; Wu, C; Xu, J; Xu, N; Xu, R; Yang, L; Yu, Z; Yuan, Y; Zhang, B; Zhong, H; Zhou, J | 1 |
| Antognelli, C; Aristei, C; Calzuola, M; Del Papa, B; Palumbo, I; Piattoni, S; Talesa, VN | 1 |
| Cai, X; Gao, J; Gu, Y; Guo, W; Sun, Y; Wang, B; Wang, Y; Wei, B; Xu, L; Xu, Q; Zhong, H | 1 |
| Hou, X; Hua, X; Huang, Y; Peng, Z; Xie, T | 1 |
| Tian, H; Yan, J; Yang, S; Zhang, Y; Zhao, H | 1 |
| Batra, A; Cheung, WY; Hannouf, MB; Rigo, R | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, Z; Cheng, Y; Deng, Y; Guo, W; Guo, X; Han, R; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shu, Y; Su, W; Sun, S; Wang, H; Wang, J; Wang, N; Wang, S; Wu, C; Xu, J; Xu, N; Xu, R; Yang, L; Yu, Z; Yuan, Y; Zhang, B; Zhong, H; Zhou, J | 1 |
| Bai, Y; Chen, Y; Chen, Z; Deng, Y; Fan, S; Guo, W; Guo, X; Li, H; Li, J; Pan, H; Peng, C; Peng, M; Qin, S; Shen, L; Shu, Y; Wang, N; Xu, J; Xu, RH; Yang, L; Zhong, H | 1 |
| Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X | 1 |
| Arnhof, H; Bader, G; Böttcher, J; Ettmayer, P; Gerstberger, T; Gmachl, M; Haering, D; Hauer, K; Hela, W; Hofmann, MH; Kennedy, MD; Kessler, D; Kofink, C; Kraut, N; Lamarre, L; McConnell, DB; Mendes, RL; Meyer, R; Munico-Martinez, S; O'Connell, JC; Pototschnig, N; Ramharter, J; Richard, D; Rumpel, K; Salamon, C; Sanderson, M; Schnitzer, R; Weiner, I; Werni, P; Wolkerstorfer, B; Wunberg, T; Zöphel, A | 1 |
| Christenson, ES; Cui, J; DePasquale, M; Egleston, M; Gizzi, A; Orris, B; Park, BH; Seamon, KJ; Stivers, JT | 1 |
| Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW | 1 |
| Chien, C; Dasari, A; Eng, C; Kania, M; Schelman, W; Sobrero, A; Tabernero, J; Yang, Z; Yao, J; Yoshino, T | 1 |
| Jiang, FE; Liu, AN; Yu, CY; Zhang, HJ | 1 |
| Gu, JK; Hao, M; Jiang, HD; Jim Wang, ZJ; Ju, HX; Li, L; Xu, MC; Yang, ZZ; Yu, LS; Zeng, S | 1 |
| Cai, G; Cai, S; Chen, Y; Li, Y; Liang, X; Liu, J; Meng, X; Qi, Y; Qiu, C; Xu, Y; Zheng, H | 1 |
| Han, C; Jiang, D; Li, J; Wang, M; Wang, X; Ye, Y; Zhao, C | 1 |
| Adams, R; Brown, E; Brown, L; Butler, R; Falk, S; Fisher, D; Kaplan, R; Maughan, T; Quirke, P; Richman, S; Samuel, L; Seligmann, J; Seymour, M; Shiu, KK; Wasan, H; Wilson, R | 1 |
| Huang, A; Lin, Z; Liu, T; Ma, H; Yao, J; Zhang, S; Zhang, T | 1 |
| Haglund, C; Hermunen, K; Lantto, E; Österlund, P; Poussa, T | 1 |
| Chu, E | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, ZD; Cheng, Y; Deng, Y; Fan, S; Guo, W; Hua, Y; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shen, L; Shu, Y; Su, W; Sun, S; Wang, H; Wang, J; Wang, S; Wu, C; Xu, J; Xu, N; Xu, RH; Yang, L; Yu, Z; Yuan, Y; Zhong, H; Zhou, J | 1 |
| Burki, TK | 1 |
| Bi, F; Bi, NX; Gong, QY; Liu, BS; Liu, Q; Nie, YZ; Tang, QL; Xia, HW; Zhou, JT; Zhou, S | 1 |
| Cao, H; Ding, W; Li, C; Li, W; Liu, R; Lu, L; Shao, G; Song, J; Wang, J; Xiang, H; Yang, J; Yang, Z | 1 |
| He, XH; Huang, HZ; Li, GD; Li, WT; Wang, GZ; Wang, Y; Wang, YH; Wei, N; Xu, LC; Zhang, B | 1 |
| Shirley, M | 1 |
| Han, X; Li, HY; Li, J; Liao, J; Peng, B; Shi, R; Wang, FC; Wang, H; Wang, WZ; Xiao, BB; Xu, X; Yang, CR; Yuan, XL | 1 |
| Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Wu, J; Yang, Y; Yi, C | 1 |
| Chen, DL; Chen, Y; Guo, XX; Jiang, R; Li, J; Li, XP; Lv, XT; Lv, YW; Ran, JH; Tian, K; Yuan, DZ; Zhou, P | 1 |
| Chen, Z; Jiang, L | 1 |
| Binglan, Z; Jing, Z; Rui, Z | 1 |
| Landry, MR; Rosch, JG; Sun, C; Thomas, CR | 1 |
| Cai, G; Cai, J; Gao, R; Ji, Q; Li, C; Li, Q; Song, D; Sui, H; Teng, P; Wang, Y; Zhou, L | 1 |
| Brooks, L; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Robertson, JD; Schmoll, HJ; Taboada, M; Wilson, D | 1 |
| Brooks, L; Dearden, S; Hoff, PM; Jürgensmeier, JM; McWalter, G; Morgan, SR; Robertson, JD; Smith, JC; Wilson, D | 1 |
| Cassidy, J; Hochster, H | 1 |
| Chen, HJ; Fushiya, S; Hour, MJ; Jiang, YL; Lin, CM; Peng, SF; Tsai, SC; Yang, JS | 1 |
| Berglund, A; Bergström, D; De Pont Christensen, R; Fernebro, E; Frödin, JE; Garm Spindler, KL; Hagman, H; Jakobsen, A; Johnsson, A; Keldsen, N; Sundberg, J | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Piccart, M | 1 |
| Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Jiao, S; Liu, T; Xie, X; Yang, J; Zhang, G | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 1 |
| Avallone, A; Budillon, A; Di Gennaro, E; Iaffaioli, VR; Silvestro, L | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK | 1 |
| Guan, W; Hu, J; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zhang, Q | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Bar, J; Brooks, L; Cunningham, D; Goss, GD; Jürgensmeier, JM; Morgan, S; Robertson, J; Spencer, S | 1 |
| Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W | 1 |
| Ge, H; Guan, L; Liu, X; Sun, M; Sun, X; Xiao, Q; Zhang, H; Zhang, Y | 1 |
| Buck, JR; Cheung, YY; Coffey, RJ; Dawson, ES; Hight, MR; Manning, HC; Nickels, ML; Saleh, S; Tang, D; Washington, MK; Zhao, P | 1 |
| Benekli, M; Bozkurt, O; Buyukberber, S; Ciltas, A; Demirci, U; Eren, T; Isikdogan, A; Kaplan, MA; Karaca, H; Kodaz, H; Ozkan, M; Sevinc, A | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F | 1 |
| Chang, J; Cheng, CC; Guan, SS; Ho, AS; Liu, SH; Luo, TY; Wang, CC; Wu, CT | 1 |
| Chen, CH; Chen, YC; Chien, CC; Ko, CH; Shen, SC; Wu, MS; Yang, LL | 1 |
| Fujita, M; Hara, M; Ito, Y; Kanemitsu, Y; Kondo, E; Nakanishi, H; Nakata, S; Tanaka, H; Yatabe, Y | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Shaw, R; Spencer, SK | 1 |
| Braun, M; Cassidy, J; Chau, I; Falk, S; Finnigan, H; Ford, H; Harrison, M; Hickish, T; Iveson, T; Jones, H; Lee, C; Macpherson, IR; Potter, V; Propper, D | 1 |
| Boeck, S; Bruns, CJ; Camaj, P; Gamba, S; Giessen, C; Haertl, C; Heinemann, V; Laubender, RP; Modest, DP; Stintzing, S; Wang, Y; Zhao, Y | 1 |
| Bi, J; Ke, Y; Liu, T; Ma, H; Zhang, S; Zhang, T | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH | 1 |
| Carreres-Prieto, M; Layos-Romero, L; López-Sisamón, D | 1 |
| Abbruzzese, JL; Eng, C; Fogelman, D; Gallick, G; Jacobs, C; Jimenez, CA; Kopetz, S; Malik, Z; Morris, J; Overman, MJ; Parikh, N; Qiao, W; Reddy, SM; Shureiqi, I; Wolff, RA | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Bertotti, A; Bose, R; Cottino, F; Galimi, F; Jacobs, SA; Jain, N; Kavuri, SM; Leto, SM; Migliardi, G; Monsey, J; Searleman, AC; Shen, W; Trusolino, L | 1 |
| Essapen, S; Fan, Z; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Aprile, G; Bencardino, K; Ciardiello, F; Frau, B; Gambacorta, M; Garufi, C; Graiff, C; Grigioni, W; Labianca, R; Lauricella, C; Leone, F; Lonardi, S; Loupakis, F; Marsoni, S; Martino, C; Mosconi, S; Noe, J; Penaullt-Llorca, F; Pinto, C; Racca, P; Risio, M; Rugge, M; Sartore-Bianchi, A; Siena, S; Tonini, G; Truini, M; Valtorta, E; Veronese, S; Viale, G; Zagonel, V | 1 |
| Han, BW; Hou, BX; Li, YW; Luo, XY; Ma, ZK; Nie, PP; Shi, XP; Zou, ZZ | 1 |
| Chen, X; He, L; Li, M; Li, Q; Li, T; Xu, X; Zhang, D | 1 |
| Chen, DL; Feng, ZQ; Li, J; Liao, K; Luo, N; Shi, QQ; Zhao, LC | 1 |
| Chen, ZS; Deng, WL; Fu, XL; Huang, JP; Ji, Q; Li, Q; Liu, X; Sui, H; Wen, HT; Zhang, YL; Zhou, LH; Zhu, HR | 1 |
| Barry, ST; Campbell, H; Critchlow, SE; Eberlein, C; Farren, M; Frith, J; Huby, R; Kendrew, J; Michopoulos, F; Morgan, S; Patel, B; Pommier, AJ; Robertson, J; Smith, NR; Smith, PD; Wappett, M; Womack, C | 1 |
| Ananthan, S; Li, Y; Lu, W; Moukha-Chafiq, O; Pathak, V; Saini, SK | 1 |
| Fan, Z; Lu, Y; Qiu, S; Shi, C | 1 |
| Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V | 1 |
| De Pauw, I; Deschoolmeester, V; Lardon, F; Pauwels, P; Peeters, M; Van den Bossche, J; Vermorken, JB; Wouters, A | 1 |
| Goto, N; Inoue, T; Kashimoto, S; Kukimoto-Niino, M; Masuda, M; Mimata, A; Moriyama, H; Ohata, H; Ohbayashi, N; Okamoto, K; Sawa, M; Shirouzu, M; Uno, Y; Yamada, T | 1 |
| Chen, Y; Chen, ZS; Huang, JR; Jiang, QW; Li, Y; Qin, WM; Qiu, JG; Shi, Z; Wang, K; Wang, YJ; Wei, MN; Yang, DH; Yang, Y; Zhang, WJ; Zheng, DW | 1 |
| Ceelen, W; Descamps, B; Melsens, E; Pattyn, P; Rosseel, N; Vanhove, C; Verberckmoes, B | 1 |
| Bai, Y; Cao, J; Fan, S; Hua, Y; Li, J; Liu, T; Pan, H; Shen, L; Su, W; Wang, L; Xu, J; Xu, RH; Zhang, D | 1 |
| Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X | 1 |
| Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M | 1 |
| Bissonnette, M; Koetsier, JL; Kunte, DP; Roy, HK; Wali, RK | 1 |
| Bradley, DP; Jürgensmeier, JM; Kilburn, L; Lacey, T; Mills, J; Odedra, R; Scott, M; Tessier, JJ; Wedge, SR | 1 |
| Fennell, DA; Johnston, PG; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, S; Van Schaeybroeck, S | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI | 1 |
| Gibbs, P; Godwood, A; Michael, M; Oliver, S; Smith, R; Tebbutt, N | 1 |
| Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Godwood, A; Oliver, S; Peeters, M; Saunders, MP; Smith, R; Van Cutsem, E; Wilson, R | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ | 1 |
| Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J | 1 |
| Avallone, A; Bruzzese, F; Budillon, A; Delrio, P; Di Gennaro, E; Leone, A; Pepe, S; Subbarayan, PR | 1 |
| Hasmann, M; Klein-Scory, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schoeneck, A; Schulmann, K; Schwarte-Waldhoff, I; Stricker, I; Tannapfel, A | 1 |
| Chen, AQ; Liu, B; Yang, ZG | 1 |
| Arndt, KT; Ayral-Kaloustian, S; Chaudhary, I; Chen, L; Chen, Z; Dehnhardt, CM; Delos Santos, E; Dos Santos, O; Geng, Y; Lucas, J; Mansour, TS; Venkatesan, AM | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Burd, R; Daskalakis, C; Dicker, AP; Ryan, A; Wachsberger, P | 1 |
| Malfair Taylor, SC; Wilson, KS | 1 |
| Bijnsdorp, IV; Fukushima, M; Gokoel, S; Kruyt, FA; Peters, GJ; Smid, K | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Arndt, K; Ayral-Kaloustian, S; Brooijmans, N; Chaudhary, I; Chen, L; Chen, Z; Curran, K; Dehnhardt, CM; Dejoy, SQ; Delos Santos, E; Diesl, V; Dos Santos, O; Follettie, MT; Geng, Y; Lucas, J; Mansour, TS; Petersen, R; Venkatesan, AM | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Bishop, WR; Dasmahapatra, B; Demma, M; Doll, R; Hesk, D; Li, C; Liang, L; Liu, M; Mallams, A; Maxwell, E; Ramos, R; Rossman, R; Seidel-Dugan, C | 1 |
| Bovio, H; de Sande González, L; García-Foncillas, J; García-Girón, C; García-López, JL; Lacave, AJ; Peláez, I; Reboredo, M; Valladares, M; Viéitez, JM | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Cercueil, JP; Chauffert, B; Ghiringhelli, F; Guiu, B; Khouri, C; Ladoire, S | 1 |
| Ban, HS; Nakamura, H; Uno, M | 1 |
| Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C | 1 |
| Wörmann, B | 1 |
| Arcaroli, JJ; Eckhardt, SG; Elvin, P; Gao, D; Messersmith, WA; Powell, RW; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Dibirdik, I; Uckun, FM | 1 |
| Fenning, CS; Fenton, A; Johnston, PG; Kyula, JN; Longley, DB; Sasazuki, T; Shirasawa, S; Van Schaeybroeck, S | 1 |
| Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| El-Khoueiry, A; Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Russell, J; Wilson, PM | 1 |
| Chen, Y; Ding, Z; Li, J; Liang, H; Pan, F; Peng, Q; Ran, L; Yang, L; Zhao, X | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K | 1 |
| Essapen, S; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 2 |
| Amellal, N; Andre, T; Bouche, O; De Gramont, A; Ducreux, M; Lledo, G; Maindrault-Goebel, F; Merger, M; Stopfer, P | 1 |
| Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| André, T; Battistella, A; Boudou, P; Cervera, P; Chibaudel, B; de Gramont, A; Dumont, S; El Ouadrani, K; Escargueil, AE; Fléjou, JF; Kamsu-Kom, N; Larsen, AK; Mégalophonos, VF; Ouaret, D; Petitprez, A; Poindessous, V; Tournigand, C | 1 |
| Bonnefoy, M; Falandry, C; Freyer, G | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Albanell, J; Bellmunt, J; Bellosillo, B; Bosch, F; Crespo, M; Dalmases, A; Gallen, M; Himmelbauer, H; Iglesias, M; Marsters, S; Minoche, A; Montagut, C; Pairet, S; Rovira, A; Salido, M; Serrano, S; Seshagiri, S; Settleman, J; Somasekar, S; Tsai, SP | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Alli, C; Alzani, R; Avanzi, N; Ballinari, D; Beria, I; Cappella, P; Caruso, M; Casolaro, A; Ciavolella, A; Cucchi, U; De Ponti, A; Felder, E; Fiorentini, F; Galvani, A; Gianellini, LM; Giorgini, ML; Isacchi, A; Lansen, J; Moll, J; Pesenti, E; Rizzi, S; Rocchetti, M; Sola, F; Valsasina, B | 1 |
| Azad, A; Chong, G; Dobrovic, A; Fluck, K; Gebski, V; Johns, TG; Mariadason, JM; Pavlakis, N; Price, TJ; Salemi, R; Scott, AM; Skrinos, E; Tebbutt, NC; Weickhardt, AJ | 1 |
| Bigot, L; Boige, V; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Goéré, D; Gonin, P; Marion, S; Noël-Hudson, MS; Polrot, M | 1 |
| Bellail, AC; Gao, S; Hao, C; Li, B; Liu, T; Wei, F | 1 |
| Arcaroli, JJ; Bemis, L; Dasari, A; Eckhardt, SG; Messersmith, WA; Pitts, TM; Powell, RW; Quackenbush, KS; Reinemann, JM; Spreafico, A; Tan, AC; Touban, BM; Varella-Garcia, M | 1 |
| Lo, RS | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
| Abrams, TA; Ancukiewicz, M; Blaszkowsky, L; Chan, JA; Duda, DG; Elliott, M; Enzinger, PC; Goldstein, M; Jain, RK; Kulke, MH; Meyerhardt, JA; Regan, E; Schrag, D; Wolpin, BM; Zhu, AX | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Rinella, ES; Threadgill, DW | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Cortés-Funes, H; Esteban, B; García-Carbonero, R; García-Girón, C; García-Rico, E; Gravalos, C; León, AI; Maurel, J; Murias, A; Salut, A; Sevilla, I | 1 |
| Alferez, DG; Anderson, E; Crafter, C; Goodlad, RA; Odedra, R; Ryan, AJ; Sini, P; Wedge, SR; Wilkinson, RW; Wright, NA | 1 |
| Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Jing, CQ; Li, LP; Tian, SB | 1 |
| Ashraf, SQ; Bodmer, WF; Mortensen, NJ; Nicholls, AM; Ntouroupi, TG; Wilding, JL | 1 |
| Haglund, C; Hermunen, K; Osterlund, P | 1 |
| Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Balteskard, L; Edna, TH; Laino, R; Norum, J; Rønning, G; Wählby, L | 1 |
| Barthelemy, P; Becouarn, Y; Bennouna, J; Bertheault-Cvitkovic, F; Conroy, T; Douillard, JY; Fandi, A; François, E; Gamelin, E; Nasca, S; Paillot, B; Raoul, JL; Seitz, JF; Ychou, M | 1 |
| Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL | 1 |
| Andreoli, F; Bacci, G; Doni, L; Fulignati, C; Martini, V; Moretti, R; Neri, B; Pantalone, D; Perfetto, F; Pernice, LM; Poma, A; Sancez, L; Taruffi, F; Turrini, M; Valeri, A | 1 |
| Avvisati, G; Dicuonzo, G; Finolezzi, E; Salerno, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Carnaghi, C; Fallini, M; Garassino, I; Masci, G; Morenghi, E; Rimassa, L; Santoro, A; Zucali, PA | 1 |
| Aristides, M; Chen, J; Clarke, S; Grant, K; Schulz, M; Williamson, E | 1 |
| Ranson, M | 1 |
| Markó, L; Sárkány, J; Szûcs, M; Tóth, K | 1 |
| Depisch, D; Fiebiger, W; Kornek, GV; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Benson, AB; O'dwyer, PJ | 1 |
| Scheithauer, W; Schüll, B | 1 |
| D'Orazio, AI; Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Rosen, LS | 1 |
| Aherne, GW; Brabender, J; Cunningham, D; Danenberg, KD; Danenberg, PV; Farrugia, DC; Ford, HE; Hardcastle, A; Jackman, AL; McCarthy, K; McVicar, AD | 1 |
| Cain, D; James, RD; Kerr, DJ; Ledermann, JA; Maughan, TS; McArdle, C; Seymour, MT; Stephens, RJ; Topham, C | 1 |
| Cohen, RB | 1 |
| Lorusso, PM | 1 |
| Schiller, JH | 1 |
| Comte, S; Lebrun, T; Selke, B | 1 |
| Glimelius, B | 1 |
| Lièvre, A; Mitry, E | 1 |
| Douglass, EC | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM | 1 |
| Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D | 1 |
| Dvorák, J; Kohout, P; Melichar, B; Melicharová, K; Solichová, D; Zadák, Z | 1 |
| Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A | 1 |
| Garcia-Vargas, J; Thomas, RJ; Williams, M | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L | 1 |
| Aiba, K; Horikoshi, N; Koizumi, W; Sasaki, T; Sato, A | 1 |
| Yamada, K; Yamaguchi, S; Yamamura, T | 1 |
| Ackland, SP; Howitt, IJ; McCluskey, A; Sakoff, JA | 1 |
| Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y | 1 |
| Cats, A | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Bertino, J; Dimery, I; Endres, S; Kelsen, DK; Kemeny, N; Saltz, L; Schwartz, GK; Tong, W; Welch, M | 1 |
| Bianco, V; Bonsignori, M; Campisi, C; D'Angelillo, RM; Marcucci, F; Massacesi, C; Pilone, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Barón, MG; Castañón, C; de Tejada, MR; Escudero, P; Feliu, J; López-Gómez, L; Martín, MS; Martínez, MP; Pericay, C; Rodríguez-García, JM; Salud, A; Sánchez, JJ | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Canfield, V; Douglass, E; Keller, A; Parker, G; Schulz, J | 1 |
| Li, YL; Wu, SG | 1 |
| Doyle, B; Geller, JI; Houghton, JA; Petak, I; Szekely-Szucs, K | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Von Pawel, J | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Barnard, GF; Inoue, H; Ishii, H; Ishikawa, K; Mimori, K; Mori, M; Ohta, M; Utsunomiya, T; Yamashita, K; Yoshinaga, K | 1 |
| Arnheim, K | 1 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Boucher, E; Boudjema, K; de Guibert, S; Egreteau, J; Jacquelinet, C; Meunier, B; Raoul, JL | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Batist, G; Douglas, L; Glenwood, G; Goel, R; Hirte, HW; Jean, M; Lorimer, IA; Mackenzie, MJ; Major, PP; Matthews, S; Miller, WH; Panasci, L; Seymour, L | 1 |
| Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM | 1 |
| Poston, GJ | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Artale, S; Bardelli, A; Benvenuti, S; Moroni, M; Sartore-Bianchi, A; Siena, S | 1 |
| Friberg, G; Kindler, HL; Skoog, L; Vokes, EE; Wade-Oliver, K | 1 |
| Blanke, CD | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Ganti, AK; Potti, A | 1 |
| Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Allen, W; Galligan, L; Johnston, PG; Longley, DB; McDermott, U; Wilson, T | 1 |
| Soff, G; Zakarija, A | 1 |
| Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Castañón, C; Castro, J; Escudero, P; Feliu, J; González, E; González-Barón, M; Juárez, F; Lizón, J; López-Gómez, L; Mel, JR; Pelegrín, A; Ruiz, M; Salud, A | 1 |
| Chiritescu, G; Cripps, C; Fisher, B; Goel, R; Jonker, D; Kocha, W; Lister, D; Malpage, A; Maroun, JA; Seymour, L; Vincent, M | 1 |
| Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Brose, MS; Flaherty, KT | 1 |
| Bhattacharya, A; Cao, S; Durrani, FA; Fakih, M | 1 |
| Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M | 1 |
| Demlová, R; Dusek, L; Jarkovský, J; Kiss, I; Kocáková, I; Vyzula, R | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Sikic, BI | 1 |
| Boddy, AV; Graham-Cole, CL; Hesp, R; Melton, RG; Newell, DR; Taylor, GA; Thomas, HD | 1 |
| Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F | 1 |
| Brazelle, WD; Shi, W; Siemann, DW | 1 |
| Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Eng, C; Shalan, N | 1 |
| Bedenne, L; Berger, C; Bouche, O; Cassan, P; Ducreux, M; Dunant, A; Fournet, J; Leduc, B; Mousseau, M; Pignon, JP; Raoul, JL | 1 |
| Cunningham, MP; Fan, Z; Modjtahedi, H; Thomas, H | 1 |
| Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L | 1 |
| Funk, G; Kornek, GV; Oehler, L; Scheithauer, W; Schwarz, C; Urbauer, E; Wenzel, C | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Adames, V; Chen, J; Fritzky, L; Higgins, B; Kolinsky, K; Linn, M; Mehta, N; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| García-Foncillas, J; Gil, C; Monreal, I; Rodríguez, J; Salgado, J; Zabalegui, N | 1 |
| Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX | 1 |
| Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A | 1 |
| Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J | 1 |
| Barr, S; Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Sennello, R; Thompson, S; Young, D | 1 |
| Babur, M; Shannon, AM; Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
| Abbas, M; Aupérin, A; Bedenne, L; Borget, I; Bouché, O; Cassan, P; Clavero-Fabri, MC; Ducreux, M; Mousseau, M; Nasca, S; Pignon, JP; Queuniet, AM; Raoul, JL; Stremsdoerfer, N | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Chick, J; Clamp, AR; Debois, M; Govaerts, AS; Jayson, GC; Lacombe, D; Marreaud, S; Schöffski, P; Twelves, C; Valle, JW; Wilson, RH | 1 |
| Avallone, A; Bruzzese, F; Budillon, A; Caraglia, M; Comella, P; Delrio, P; Di Gennaro, E; Laus, G; Pepe, S | 1 |
| Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Kibble, A | 1 |
| Buchanan, FG; DuBois, RN; Holla, V; Katkuri, S; Matta, P | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Ng, K; Zhu, AX | 1 |
| Barnett, JB; Fitzgerald, CA; Gill, S; Khoo, KE; Wilson, KS | 1 |
| Ardizzoni, A; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Crocicchio, F; Labianca, R; Mari, E; Pucci, F; Salvagni, S; Scartozzi, M; Sobrero, A; Tagliaferri, P | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Bridgewater, J; Glynne-Jones, R; Harrison, M; Propper, D; Stebbing, J | 1 |
| Biffi, R; Chiappa, A; de Braud, F; Dell'Orto, P; Fazio, N; Magni, E; Monfardini, L; Santoro, L; Sonzogni, A; Zampino, MG; Zorzino, L | 1 |
| Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I | 1 |
| Curwen, JO; Kendrew, J; Musgrove, HL; Ogilvie, DJ; Richmond, GH; Wedge, SR | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Herrmann, R | 1 |
| Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR | 1 |
| Adenis, A; Azab, M; Cunningham, D; Francois, E; Green, M; Iveson, A; Schornagel, J; Seymour, I; Van Cutsem, E; Zalcberg, JR | 1 |
| Bleiberg, H | 3 |
| Mead, GM | 1 |
| Aiba, K | 1 |
| Burris, H; Cunningham, D; Gore, M; Kennealey, G; Meropol, NJ; Pazdur, R; Seymour, L; Smith, I; Zalcberg, J | 1 |
| Cheson, BD; Phillips, PH; Sorensen, JM | 1 |
| Cunningham, D; Heron, J; Ross, P | 1 |
| Boyle, FT; Harrap, KR; Jackman, AL | 1 |
| Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H; Yin, MB | 1 |
| Cunningham, D; Harper, P; Kerr, D; Oliver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; van Cutsem, E; Zalcberg, JR | 1 |
| Borud, K; Isacoff, WH | 1 |
| Kerr, DJ | 1 |
| Sobrero, A | 1 |
| Zalcberg, J | 1 |
| Kerr, DJ; O'Connor, KM | 1 |
| Van Cutsem, E | 2 |
| Judson, IR | 1 |
| Faulds, D; Gunasekara, NS | 1 |
| Anderson, H; Palmer, MK | 1 |
| Cunningham, D | 1 |
| Blackledge, G | 1 |
| Punt, CJ | 1 |
| Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G | 1 |
| Millward, MJ; Stewart, JM; Zalcberg, JR | 1 |
| Cunningham, D; Farrugia, DC; Norman, AR | 1 |
| Kerr, D; Palmer, M; Seymour, L; Zalcberg, J | 1 |
| Folkes, A; Nutting, C | 1 |
| Byttebier, G; Groener, MG; Rutten, FF; van Hout, BA; van Ineveld, BM | 1 |
| Hochegger, K; Marian, B; Partik, G; Schörkhuber, M | 1 |
| Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR | 1 |
| Adjei, AA | 1 |
| Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ | 1 |
| Aiba, K; Horikoshi, N; Kikkawa, N; Kurihara, M; Mitachi, Y; Sakata, Y; Sato, A; Shirouzu, K; Wakui, A | 1 |
| Bertino, JR; Gorlick, R | 1 |
| Cao, S; Rustum, YM | 1 |
| Danenberg, PV; Malli, H; Swenson, S | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J | 1 |
| González Barón, M; Harstrick, A; Schwartz, GK | 1 |
| Armand, JP; Evans, TR; Seymour, L | 1 |
| Danenberg, PV; Lehman, NL | 1 |
| Downes, M; Evans, V; Kay, S; Moore, J; Topham, C; Turner, J; Wardle, J; Young, A | 1 |
| Endo, W; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
| Heyes, A; Palmer, MK; Sculpher, M | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Mitry, E; Rougier, P | 1 |
| Cassidy, J | 1 |
| Cunningham, D; Sumpter, K | 1 |
| Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S | 1 |
| Hoff, PM; Padzur, R; Royce, ME | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Arvelo, F; Bras-Gonçalves, RA; Coquelle, A; De Pinieux, G; Dutrillaux, B; Formento, JL; Lesuffleur, T; Milano, G; Pandrea, I; Pocard, M; Poirson-Bichat, F; Poupon, MF; Ronco, G; Villa, P | 1 |
| Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Penz, M; Raderer, M; Salek, T; Scheithauer, W; Ulrich-Pur, H | 1 |
| Cunningham, D; James, RD | 1 |
| Ganser, A; Reinke, F; Schlichting, C; Schöffski, P; van Gennip, AH; van Kuilenburg, AB; Volk, J | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H | 1 |
| Louvet, C | 1 |
| Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P | 1 |
| Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P | 1 |
| Armand, JP; Becouarn, Y; Ducreux, M; Fizazi, K; Seitz, JF | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Calvert, AH; Cunningham, D; Farrugia, DC; Ford, HE; Hill, ME; Jackman, AL; Judson, IR; Mitchell, F; Rees, C | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Clarke, S; Cunningham, D; Facchini, T; González Barón, M; James, R; Maroun, J; Maughan, TS; Schulz, J; Vincent, M; Zalcberg, J | 1 |
| Holen, KD; Saltz, LB | 1 |
| Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
| Bansback, N; Hummel, S; Lloyd Jones, M; Orr, B; Seymour, M | 1 |
| Angelopoulou, A; Fotia, M; Kontos, A; Kosmas, C; Koufos, Ch; Sougioultzis, S; Soulla, M; Tsavaris, N; Vadiaka, M; Vrizidis, N | 1 |
| Aparicio, J; Camps, C; Escudero, P; Feliu, J; García Girón, C; González Barón, M; Mel, JR; Menéndez, D; Rodriguez, MR; Sánchez, JJ | 1 |
| Cervantes, A; Cunningham, D; Glimelius, B; Maroun, J; Van Cutsem, E | 1 |
| Barrie, E; Kelland, LR; Rowlands, MG; Smith, V; Workman, P | 1 |
| Antognoli, S; Baldelli, AM; Barni, S; Battelli, N; Cascinu, S; Catalano, V; Ferraù, F; Giordani, P; Graziano, F; Labianca, R; Maisano, R; Mari, D; Massacesi, C; Pessi, MA; Priolo, D; Rota, S; Santini, D; Siena, S; Silva, RR; Tonini, G; Zaniboni, A | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S | 1 |
| Allen, MJ; Cunningham, D; Hill, ME; Maisey, NR; Norman, A; Watson, M | 1 |
| Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Jackson, DE; Krakoff, IH; Levin, B; Patt, YZ | 1 |
90 review(s) available for quinazolines and Colorectal Neoplasms
| Article | Year |
|---|---|
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2019 |
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil | 2020 |
Fruquintinib: First Global Approval.
Topics: Antineoplastic Agents; Benzofurans; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
The clinical application of fruquintinib on colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzofurans; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2019 |
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Topics: Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Quinazolines; Treatment Outcome | 2019 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Humans; Quinazolines; Thiophenes; Thymidylate Synthase | 2014 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mucositis; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Stomatitis; Thiophenes; Vomiting | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2014 |
Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Quinazolines; Vascular Endothelial Growth Factors | 2016 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Raltitrexed: optimism and reality.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes; Thymidylate Synthase; Tissue Distribution | 2009 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Prognostic significance and targeting of HER family in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Panitumumab; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Levamisole; Palliative Care; Quality-Adjusted Life Years; Quinazolines; Thiophenes | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2003 |
Development of ZD1839 in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Floxuridine; Fluorouracil; Forecasting; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quinazolines; Thiophenes | 2003 |
[Angiogenesis and metastasis in colorectal cancer].
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quinazolines; Thiophenes; United Kingdom | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2008 |
Thymidylate synthase inhibition, a dead end?
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Quinazolines; Thiophenes; Thymidylate Synthase | 1995 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1996 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Quinazolines; Remission Induction; Thiophenes; Thymidylate Synthase | 1996 |
Raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes | 1996 |
Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Design; Drugs, Investigational; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Quinazolines; Thiophenes; Thymidylate Synthase | 1996 |
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Damage; DNA, Neoplasm; Drug Resistance; Fluorouracil; Folic Acid Antagonists; Forecasting; Humans; Prodrugs; Quinazolines; Thiophenes; Thymidylate Synthase | 1997 |
Colorectal cancer--is there an alternative to 5-FU?
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Quinazolines; Thiophenes; Thymidylate Synthase | 1997 |
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Quinazolines; Thiophenes; Thymidylate Synthase; Trimetrexate | 1997 |
Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Quinazolines; Thiophenes | 1997 |
Talking 'Tomudex': introduction.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes | 1997 |
Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes | 1997 |
The costs of managing advanced colorectal cancer: a broad perspective.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes | 1997 |
Future developments with 'Tomudex' (raltitrexed).
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Quinazolines; Thiophenes | 1997 |
'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Humans; Quinazolines; Thiophenes | 1997 |
Continuing the fight against advanced colorectal cancer: new and future treatment options.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
Mature results from three large controlled studies with raltitrexed ('Tomudex').
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Humans; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Drug resistance in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Gene Expression; Humans; Quinazolines; Thiophenes; Thymidylate Synthase | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Oxidoreductases; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidine Phosphorylase; Thymidylate Synthase; Uracil | 1999 |
Thymidylate synthase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Isoindoles; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1999 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Thymidylate synthase inhibitors in colorectal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid; Glutamates; Guanine; Humans; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2000 |
Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexed.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Humans; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Quinazolines; Thiophenes | 1999 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[New chemotherapies for colorectal cancer treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes | 2001 |
[Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pain; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Vomiting | 2002 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil | 2001 |
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; England; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Treatment Outcome; Wales | 2001 |
Raltitrexed: current clinical status and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2002 |
134 trial(s) available for quinazolines and Colorectal Neoplasms
| Article | Year |
|---|---|
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2023 |
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Topics: Benzofurans; China; Colorectal Neoplasms; Humans; Quinazolines | 2020 |
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Topics: Aged; Benzofurans; Colorectal Neoplasms; Double-Blind Method; ErbB Receptors; Female; Humans; Male; Middle Aged; Progression-Free Survival; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2021 |
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Quinazolines; Thiophenes | 2021 |
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzofurans; Colorectal Neoplasms; Double-Blind Method; Humans; Protein Kinase Inhibitors; Quinazolines | 2021 |
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Topics: Aged; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Survival Analysis | 2018 |
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Thiophenes; Tomography, X-Ray Computed | 2018 |
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; China; Colorectal Neoplasms; Combined Modality Therapy; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A; Young Adult | 2018 |
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Quinazolines; Tegafur; Thiophenes | 2019 |
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Quinazolines; Thiophenes; Treatment Outcome | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaloacetates; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis | 2013 |
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Isoenzymes; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leucovorin; Organoplatinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cecal Neoplasms; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2014 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Benzodioxoles; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2015 |
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Colorectal Neoplasms; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Patient Selection; Quinazolines; Receptor, ErbB-2; ROC Curve; Trastuzumab | 2015 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2016 |
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2008 |
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Treatment Outcome | 2009 |
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2009 |
Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2009 |
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Demography; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Young Adult | 2011 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Colorectal Neoplasms; Demography; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2012 |
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Male; Middle Aged; Quinazolines; Survival Rate | 2011 |
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Treatment Outcome | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Piperidines; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2012 |
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Needle; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Patient Selection; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; International Agencies; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Quinazolines; Salvage Therapy; Survival Rate; Young Adult | 2013 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Care Costs; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Norway; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pyridines; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome | 2002 |
Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2002 |
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Palliative Care; Probability; Prognosis; Quinazolines; Severity of Illness Index; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
[Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colorectal Neoplasms; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Follow-Up Studies; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Time Factors; Tumor Cells, Cultured | 2002 |
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Colorectal Neoplasms; DNA Primers; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Predictive Value of Tests; Protein Biosynthesis; Quinazolines; Radiography; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; Thymidylate Synthase; Transcription, Genetic; Treatment Outcome | 2003 |
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Staging; Palliative Care; Quinazolines; Survival Analysis; Thiophenes | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Proteins; Cell Division; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Cytoskeletal Proteins; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Trans-Activators; Tumor Suppressor Proteins | 2003 |
Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Health Education; Humans; Male; Middle Aged; Quality Assurance, Health Care; Quinazolines; Thiophenes | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies.
Topics: Adult; Colorectal Neoplasms; Drug Tolerance; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Quinazolines; Stomach Neoplasms | 2003 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Odds Ratio; Quinazolines; Survival Analysis; Thiophenes | 2004 |
Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2004 |
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Quinazolines | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2005 |
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Eruptions; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Vomiting | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 2006 |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2005 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome | 2006 |
Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2006 |
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Quinazolines; Thiophenes | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Thiophenes | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Thiophenes; Treatment Outcome | 2006 |
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitomycin; Quality of Life; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2006 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines | 2007 |
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2007 |
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost of Illness; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; France; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2006 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2007 |
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Glutarates; Humans; Isoindoles; Liposomes; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Thymidylate Synthase | 2008 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome | 2007 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Leucovorin; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Quinazolines; Survival Rate | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Pyrimidines; Quinazolines | 2008 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Length of Stay; Leucovorin; Leukopenia; Male; Middle Aged; Quality of Life; Quinazolines; Stomatitis; Survival Rate; Thiophenes | 1995 |
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Middle Aged; Quinazolines; Remission Induction; Survival Analysis; Thiophenes; Thymidylate Synthase | 1996 |
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 1996 |
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quinazolines; Thiophenes | 1996 |
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Quality of Life; Quinazolines; Surveys and Questionnaires; Thiophenes; Thymidylate Synthase | 1998 |
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Thiophenes | 1998 |
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 1998 |
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
Topics: Adult; Age Factors; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Quinazolines; Sex Factors; Thiophenes | 1998 |
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Fluorouracil; Health Care Costs; Humans; Leucovorin; Netherlands; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes | 1999 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 1999 |
Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Thiophenes; Thymidylate Synthase; Time Factors; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Quinazolines; Thiophenes | 1999 |
Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Quinazolines; Thiophenes; Treatment Outcome | 1999 |
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Digestive System Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 1999 |
A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Patient Satisfaction; Pulse Therapy, Drug; Quinazolines; Thiophenes | 1999 |
Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost of Illness; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Prospective Studies; Quinazolines; Surveys and Questionnaires; Thiophenes; Time Factors; Travel; United Kingdom | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Thiophenes; Treatment Failure | 2000 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Mitoxantrone; Neoplasms; Quinazolines; Thiophenes | 2001 |
Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes | 2002 |
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Deoxyuridine; Enzyme Inhibitors; Fluorouracil; Humans; Infusions, Intravenous; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Sex Factors; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2002 |
A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quinazolines; Trimetrexate | 1990 |
173 other study(ies) available for quinazolines and Colorectal Neoplasms
| Article | Year |
|---|---|
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Quinazolines; Rectal Neoplasms; Retrospective Studies; Thiophenes | 2022 |
BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes.
Topics: Animals; Azepines; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Quinazolines; Receptors, G-Protein-Coupled | 2022 |
Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Topics: Benzofurans; China; Colonic Neoplasms; Colorectal Neoplasms; Humans; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2022 |
Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Topics: Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Quinazolines; Rectal Neoplasms; Retrospective Studies | 2022 |
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Lung Neoplasms; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2022 |
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2023 |
Fruquintinib and its use in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Benzofurans; Cell Proliferation; China; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Acceleration of interstitial lung disease induced by raltitrexed.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Humans; Lung Diseases, Interstitial; Male; Quinazolines; Thiophenes | 2020 |
Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Colorectal Neoplasms; HCT116 Cells; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Recombinant Proteins; Thiophenes; Tumor Necrosis Factor-alpha | 2020 |
Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Berberine; Caco-2 Cells; Cardiotoxicity; Colon; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Drugs, Chinese Herbal; Epithelial Cells; HT29 Cells; Humans; Intestinal Mucosa; Myocytes, Cardiac; Quinazolines; Rats | 2020 |
Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Neoplasm Metastasis; Progression-Free Survival; Quality-Adjusted Life Years; Quinazolines | 2020 |
Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Topics: Benzofurans; Colorectal Neoplasms; Humans; Indoles; Phenylurea Compounds; Pyridines; Quinazolines; Quinolines | 2020 |
Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Humans; Pilot Projects; Quinazolines; Radiation-Sensitizing Agents | 2020 |
Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; CD8 Antigens; Cell Line, Tumor; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Disease Models, Animal; Drug Synergism; Humans; Immune Checkpoint Inhibitors; Male; Mice; Mice, Knockout; Microsatellite Instability; Programmed Cell Death 1 Receptor; Quinazolines; Receptors, Vascular Endothelial Growth Factor; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Microenvironment; Young Adult | 2020 |
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
Topics: Benzofurans; China; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Neoplasm Metastasis; Quinazolines | 2020 |
Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Colorectal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Thiophenes; Treatment Outcome | 2021 |
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Topics: Aged; Benzofurans; Cancer Survivors; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Placebos; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2021 |
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Topics: Afatinib; Allosteric Regulation; Binding Sites; Catalytic Domain; Colorectal Neoplasms; ErbB Receptors; Humans; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Protein Interaction Maps; Proto-Oncogene Proteins p21(ras); Quinazolines; SOS1 Protein | 2021 |
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Humans; Quinazolines; Thiophenes; Uracil-DNA Glycosidase | 2021 |
Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
Topics: Antibodies, Monoclonal, Humanized; Benzofurans; Colorectal Neoplasms; DNA Mismatch Repair; Humans; Microsatellite Repeats; Phenylurea Compounds; Pilot Projects; Pyridines; Quinazolines; Retrospective Studies | 2021 |
Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Azepines; Brain-Derived Neurotrophic Factor; Cancer Pain; Cell Line, Tumor; Colorectal Neoplasms; Drug Tolerance; Epigenetic Repression; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucuronosyltransferase; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Immunohistochemistry; Male; Middle Aged; Morphine; Morphine Derivatives; Neoplasm Proteins; Polycomb Repressive Complex 1; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Transcription Factors; Up-Regulation | 2017 |
A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed.
Topics: Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Half-Life; Hot Temperature; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Random Allocation; Thiophenes; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
Topics: Acrylamides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Neoplasm Proteins; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction | 2017 |
53BP1 loss suppresses the radiosensitizing effect of icotinib hydrochloride in colorectal cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Colorectal Neoplasms; Crown Ethers; DNA Damage; ErbB Receptors; HCT116 Cells; Histones; Humans; Quinazolines; Radiation-Sensitizing Agents; S Phase; Tumor Suppressor p53-Binding Protein 1 | 2018 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Fruquintinib for previously treated metastatic colorectal cancer.
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Male; Quinazolines; Salvage Therapy | 2018 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphoproteins; Polyisoprenyl Phosphates; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; China; Colorectal Neoplasms; Disease Progression; Ethiodized Oil; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Prospective Studies; Quinazolines; Survival; Thiophenes | 2018 |
Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Floxuridine; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Thiophenes; Treatment Outcome | 2019 |
Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chalcones; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Mitochondria; Quinazolines; Structure-Activity Relationship | 2019 |
Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Sirtuin 1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Enhancing chemoradiation of colorectal cancer through targeted delivery of raltitrexed by hyaluronic acid coated nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; Drug Carriers; Histones; Humans; Hyaluronic Acid; Kaplan-Meier Estimate; Liver; Mice; Mice, Inbred BALB C; Nanoparticles; Quinazolines; Radiation, Ionizing; Thiophenes; Transplantation, Heterologous | 2019 |
Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Codon; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells.
Topics: Cell Movement; Colorectal Neoplasms; ErbB Receptors; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones; Signal Transduction; Styrenes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcriptional Activation | 2013 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gefitinib; Humans; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Mutation; Pemetrexed; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase | 2013 |
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Glutamates; Guanine; Humans; Immunohistochemistry; Male; Middle Aged; Pemetrexed; Predictive Value of Tests; Quinazolines; RNA, Messenger; Thiophenes; Thymidylate Synthase | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorobenzenes; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; Indoles; Mice, Inbred C57BL; Mice, Nude; Organophosphates; Peptides; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Quinolines; Radiopharmaceuticals; Sulfonamides; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Folic Acid Antagonists; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Salvage Therapy; Tegafur; Thiophenes; Treatment Outcome; Young Adult | 2014 |
Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Compounding; Female; Hep G2 Cells; Humans; Immunoblotting; Male; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Middle Aged; Polymers; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine.
Topics: Alkylation; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; HT29 Cells; Humans; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mice; NIH 3T3 Cells; Quinazolines; Structure-Activity Relationship | 2014 |
Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Topics: Animals; Antineoplastic Agents; Butyric Acid; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2014 |
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Colorectal Neoplasms; Humans; Quinazolines; Treatment Outcome | 2014 |
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; ErbB Receptors; Exons; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3 | 2015 |
Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Colorectal Neoplasms; Crown Ethers; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; HCT116 Cells; Heterografts; HT29 Cells; Humans; Mice; Mice, Nude; Quinazolines; Radiation-Sensitizing Agents | 2015 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Biosynthesis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
[Interstitial lung disease induced by raltitrexed-oxaliplatin based chemotherapy for colorectal cancer: a case report].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Lung Diseases, Interstitial; Male; Organoplatinum Compounds; Oxaliplatin; Prednisone; Quinazolines; Thiophenes | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
HER2 activating mutations are targets for colorectal cancer treatment.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Transformation, Neoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Humans; Molecular Targeted Therapy; Mucous Membrane; Mutation; Quinazolines; Quinolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Up-Regulation | 2015 |
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation | 2016 |
Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.
Topics: Animals; Apoptosis; Cathepsin B; Cathepsin D; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitochondria; Pyrans; Quinazolines; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Topics: Antineoplastic Agents; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Nucleus; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcriptional Activation; Up-Regulation | 2015 |
Evodiamine Induces Apoptosis and Inhibits Migration of HCT-116 Human Colorectal Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Janus Kinase 2; Plant Extracts; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2015 |
Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-κB Pathway in Colorectal Cancer.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Neoplasm Proteins; NF-kappa B; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Cell Line, Tumor; Colorectal Neoplasms; Humans; Kaplan-Meier Estimate; Leptin; Melanoma, Experimental; Mice; Mice, Obese; Proportional Hazards Models; Quinazolines; Retrospective Studies; Transcriptome; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Identification of quinazoline compounds as novel potent inhibitors of Wnt/β-catenin signaling in colorectal cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Quinazolines; Wnt Signaling Pathway | 2016 |
Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Humans; Quinazolines; RNA, Small Interfering; Transcriptome; Tyrphostins | 2016 |
Colorectal Cancer Yields to Dual HER2 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Lapatinib; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
TNIK inhibition abrogates colorectal cancer stemness.
Topics: Adenomatous Polyposis Coli Protein; Administration, Oral; Aged; Animals; Azoxymethane; beta Catenin; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Neoplasms; Crystallography, X-Ray; Female; Germinal Center Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Middle Aged; Mutation; Neoplastic Stem Cells; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Recombinant Proteins; Ubiquitin-Protein Ligases; Wnt Proteins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; HT29 Cells; Humans; Male; Mice; Mice, Nude; Microvessels; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Retrospective Studies; Thiophenes; Time Factors; Treatment Outcome | 2017 |
Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.
Topics: Animals; Azoxymethane; Cell Proliferation; Chemoprevention; Colorectal Neoplasms; Down-Regulation; Epithelial Cells; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Intestinal Mucosa; Lysosomes; Male; Models, Biological; Polyethylene Glycols; Quinazolines; Rats; Rats, Inbred F344; Repressor Proteins; Snail Family Transcription Factors; Transcription Factors; Transcription, Genetic | 2008 |
Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Dose-Response Relationship, Drug; Gadolinium DTPA; Glioma; Humans; Magnetic Resonance Imaging; Quinazolines; Rats; Rats, Nude; Treatment Outcome | 2009 |
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Metalloproteases; Quinazolines; Receptor, ErbB-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; src-Family Kinases; TNF-Related Apoptosis-Inducing Ligand; Transforming Growth Factor alpha | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Leucovorin; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Suppressor Protein p53; Vorinostat | 2009 |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dimerization; Drug Therapy, Combination; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Nude; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205).
Topics: Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Evodia; G2 Phase; Humans; Membrane Potentials; Mitochondria; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.
Topics: Anilides; Animals; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Mice; Mice, Nude; Quinazolines; Structure-Activity Relationship; TCF Transcription Factors; Wnt Proteins; Xenograft Model Antitumor Assays | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Humans; Irinotecan; Mice; Mice, Nude; Piperidines; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Genes, ras; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Thymidylate Synthase; Trifluridine | 2010 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibition.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Drug Design; Humans; Mice; Quinazolines; Structure-Activity Relationship; TCF Transcription Factors; Transcription Factor 4; Transcription Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Topics: Animals; Apoptosis; Binding Sites; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Colorectal Neoplasms; DNA; Female; Humans; Immunoprecipitation; Mice; Mice, Nude; Molecular Chaperones; Mutation; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Ubiquitination; Xenograft Model Antitumor Assays | 2010 |
Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Retrospective Studies; Thiophenes | 2010 |
Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Topics: Angiogenesis Inhibitors; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; DNA-Directed DNA Polymerase; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indoles; Phenylurea Compounds; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Vascular Endothelial Growth Factor A | 2010 |
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cisplatin; Colorectal Neoplasms; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Interactions; Fluorouracil; HCT116 Cells; Humans; Models, Molecular; Organic Cation Transport Proteins; Organic Cation Transporter 2; Organoplatinum Compounds; Oxaliplatin; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Transfection | 2010 |
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.
Topics: Animals; Anticarcinogenic Agents; Colorectal Neoplasms; Janus Kinase 3; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Quinazolines | 2010 |
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Gefitinib; Genes, ras; HCT116 Cells; HT29 Cells; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, SCID; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Panobinostat; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tyrphostins | 2011 |
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Oncogene Proteins v-erbB; Quinazolines | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Topics: Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Revisiting the frontiers of pharmacogenomics of colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Hydroxamic Acids; Male; Organoplatinum Compounds; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2 | 2011 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epitopes; ErbB Receptors; Gefitinib; Humans; Mutation, Missense; Panitumumab; Quinazolines | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dogs; Female; Haplorhini; HL-60 Cells; Humans; Leukemia; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2012 |
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Colorectal Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Mice; Mice, Nude; Mutation; Quinazolines; ras Proteins; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Topics: 3' Untranslated Regions; Animals; Benzodioxoles; Biomarkers, Tumor; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Humans; Immunoblotting; Immunoprecipitation; Mice; MicroRNAs; Mutation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2012 |
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Melanoma; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor Protein-Tyrosine Kinases; Sulfonamides; Transplantation, Heterologous; Vemurafenib | 2012 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
Efficacy of EGFR inhibition is modulated by model, sex, genetic background and diet: implications for preclinical cancer prevention and therapy trials.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Colorectal Neoplasms; Diet; Disease Models, Animal; ErbB Receptors; Female; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Quinazolines; Sex Factors; Tyrphostins | 2012 |
Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
Topics: Animals; Aurora Kinase B; Cell Proliferation; Colorectal Neoplasms; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histones; Humans; Mice; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
[Effects of RNA interference and nolatrexed on thymidylate synthase expression and cell proliferation of human colorectal carcinoma LOVO cells].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; Quinazolines; RNA Interference; Thymidylate Synthase | 2012 |
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Immune System; Lapatinib; Models, Genetic; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Quinazolines; Trastuzumab | 2012 |
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Thiophenes; Tomography, X-Ray Computed | 2013 |
Raltitrexed as monochemotherapy induces a statistically significant increase in platelet count.
Topics: Aged; Antimetabolites, Antineoplastic; Blood Platelets; Colorectal Neoplasms; Hemoglobins; Humans; Middle Aged; Platelet Count; Quinazolines; Thiophenes | 2002 |
Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Australia; Colorectal Neoplasms; Data Collection; Female; Humans; Male; Middle Aged; Models, Economic; Quinazolines; Surveys and Questionnaires; Thiophenes | 2002 |
[The rare manifestation of soft tissue metastasis in colorectal cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fatal Outcome; Humans; Male; Quinazolines; Soft Tissue Neoplasms; Thiophenes | 2002 |
Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Thiophenes; Treatment Failure | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Colorectal Neoplasms; Cross-Sectional Studies; Fatigue; Female; Fever; Fluorouracil; Humans; Inflammation; Interleukin-6; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Necrosis Factor-alpha | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Intestinal Mucosa; Irinotecan; Male; Middle Aged; Permeability; Quinazolines; Thiophenes | 2003 |
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors | 2003 |
Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Topics: Antimetabolites, Antineoplastic; Cantharidin; Carcinoma; Cell Cycle; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; HT29 Cells; Humans; Phosphoprotein Phosphatases; Quinazolines; Thymidylate Synthase | 2004 |
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
[Effects of nolatrexed on thymidylate synthase protein expression].
Topics: Cell Line; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Hepatocytes; Humans; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured | 2004 |
P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells.
Topics: Apoptosis; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Enzyme Inhibitors; fas Receptor; G1 Phase; HCT116 Cells; HT29 Cells; Humans; Interferon-gamma; Purines; Quinazolines; Roscovitine; S Phase; Thymidylate Synthase | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Nucleus; Colorectal Neoplasms; Cytoplasm; DNA-Binding Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 7; Middle Aged; Phosphorylation; Protein Transport; Quinazolines; Smad4 Protein; Trans-Activators; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Quinazolines; Salvage Therapy; Time Factors | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Thiophenes; Treatment Outcome | 2005 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors | 2005 |
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mutation; Quinazolines | 2005 |
Gefitinib in colorectal cancer: if wishes were horses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; fas Receptor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; RNA, Messenger; STAT1 Transcription Factor; Thiophenes; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Antagonism; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; HT29 Cells; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Mice; Mice, Nude; Quinazolines; Reproducibility of Results; Thiophenes; Thymidine; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2007 |
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Female; HT29 Cells; Humans; Mice; Mice, Inbred Strains; Mice, Nude; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2 | 2006 |
Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonoscopy; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enterocolitis; Fatal Outcome; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Transplantation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous | 2007 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Fluorouracil; Gene Deletion; Genotype; Heterozygote; Humans; Models, Statistical; Mutation; Polymorphism, Genetic; Quinazolines; Sequence Analysis, DNA; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2007 |
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.
Topics: Biomarkers, Tumor; Cadherins; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoenzyme Techniques; Mesoderm; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis; Vimentin | 2007 |
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred CBA; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Survival Rate; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Leucovorin; Quinazolines; Thiophenes | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Intestinal Polyps; Intestine, Small; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Prostaglandins; Pyrazoles; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Thiophenes | 2007 |
Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Topics: Angiogenesis Inhibitors; Animals; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Captopril; Cell Line, Tumor; Colorectal Neoplasms; Humans; Hypertension; Mice; Nifedipine; Quinazolines; Rats; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Raltitrexed, a new drug for advanced colorectal cancer.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Humans; Infusions, Intravenous; Quinazolines; Thiophenes; Thymidylate Synthase | 1996 |
Clinical trials referral resource. Clinical trials with tomudex.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Leukemia; Male; Prostatic Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1996 |
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; England; Female; Fluorouracil; Hospital Costs; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Thiophenes | 1996 |
Second line treatment options in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mitomycin; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Myocardial Ischemia; Quinazolines; Thiophenes; Thymidylate Synthase | 1999 |
Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Membrane Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 1999 |
[The treatment of advanced colorectal carcinoma. New data emerging from the 23rd Congress of the European Society for Medical Oncology. Athens, November 1998].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Quinazolines; Radiotherapy, Adjuvant; Thiophenes | 1999 |
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Geriatrics; Humans; Leucovorin; Male; Middle Aged; Palliative Care; Prospective Studies; Quality of Life; Quinazolines; Survival Analysis; Thiophenes | 1999 |
Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Genes, p53; Humans; Phosphodiesterase Inhibitors; Quinazolines; Thiophenes; Thymidine; Tumor Cells, Cultured | 2000 |
[Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase | 2000 |
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Butyrates; Cell Differentiation; Cell Division; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA; Drug Synergism; Female; Fluorouracil; Glucose; Humans; Liver Neoplasms; Male; Methotrexate; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Thiophenes; Thymidylate Synthase; Transplantation, Heterologous | 2001 |
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Quinazolines; Thiophenes | 2001 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.
Topics: Animals; Carcinoma; Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Mice; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous | 2002 |
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Blotting, Western; Cell Division; Chromones; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Farnesyltranstransferase; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Quinolones; Transfection; Tumor Cells, Cultured | 2002 |
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Thiophenes | 2002 |